Related Experiment Videos

Treatment modalities and ANCA in Takayasu's arteritis

M Schwarz-Eywill1, A Breitbart, E Csernok

  • 1Department of Rheumatology, Medical University of Lübeck, Germany.

Insights

Takayasu

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Takayasu's Arteritis is a rare vasculitis requiring long-term immunosuppression.
  • Steroids are common but have significant long-term side effects.
  • Alternative immunosuppressive therapies are needed.

Purpose of the Study:

  • To evaluate low-dose methotrexate as an alternative immunosuppressive therapy for Takayasu's Arteritis.
  • To assess the efficacy of methotrexate in controlling disease activity and reducing steroid dependence.
  • To investigate the presence of autoantibodies (c-/p-ANCA, neutrophil granular enzymes) in patients with Takayasu's Arteritis.

Main Methods:

  • Retrospective case series of 3 patients with Takayasu's Arteritis treated with low-dose methotrexate.
  • Monitoring of disease activity and steroid dosage.
  • Screening of 16 patients for c-/p-ANCA and neutrophil granular enzymes.

Main Results:

  • Low-dose methotrexate effectively controlled disease activity in all 3 treated patients.
  • Steroid dosage was reduced or discontinued in all patients receiving methotrexate.
  • No patient screened was positive for c-/p-ANCA or neutrophil granular enzymes.

Conclusions:

  • Low-dose methotrexate is a viable and effective alternative immunosuppressive therapy for Takayasu's Arteritis.
  • Methotrexate can facilitate steroid reduction or cessation, mitigating long-term steroid-related complications.
  • Autoantibodies like c-/p-ANCA and neutrophil granular enzymes do not appear to be associated with Takayasu's Arteritis in this cohort.

Related Concept Videos